Neurogenic skin inflammation - An updated knowledge;Neurogenny stan zapalny skóry - Aktualny stan wiedzy

Postepy Dermatologii I Alergologii

Volumn 22, Issue 1, 2005, Pages 38-45

  Teresiak, Ewa ^a   Czarnecka Operacz, Magdalena ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Local immunological reaction; Neurogenic inflammation; Neuropeptides; Regulation; Vasodilatation

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; HISTAMINE; IMMUNOGLOBULIN; NEUROHORMONE; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROTRANSMITTER; NEUROTROPHIN; OPIATE;

ANTIGEN PRESENTING CELL; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CELL PROLIFERATION; CELL SURFACE; CENTRAL NERVOUS SYSTEM; ENDOCRINE FUNCTION; ENDOTHELIUM CELL; FIBROBLAST; HORMONE SYNTHESIS; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; KERATINOCYTE; MAST CELL; MYELINATED NERVE; NERVE CELL; NEUROGENIC INFLAMMATION; NEUROMODULATION; NOCICEPTIVE STIMULATION; NONMYELINATED NERVE; PARACRINE SIGNALING; PERIPHERAL NERVOUS SYSTEM; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENSORY NERVE; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; T LYMPHOCYTE; VASODILATATION;

EID: 14844346912     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Steinhoff M, Stander S, Seeliger S, et al.: Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003, 139: 1479-88.
2. Rossi R, Johansson O: Cutaneous innervation and the role of neuronal peptides in cutaneous inflammation: a minireview. Eur J Dermatol 1998, 8: 299-306.
3. Toyoda M, Nakamura M, Makino T, et al.: Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 2002, 147: 71-9.
4. Payan DG, Levine JD, Goetzl EJ: Modulation of immunity and hypersensitivity by sensory neuropeptides. J Immunol 1984, 132 (4): 1601-4.
5. Lambrecht BN: Immunologists getting nervous: neuropeptides, dendritic cells and T cell activation. Respir Res 2001, 20: 133-8.
6. Slominski A, Wortsman J: Neuroendocrinology of the skin. Endocr Rev, 2000, 21 (5): 457-87.
7. Blalock JE: Molecular basis for bidirectional communication between the immune and the neuroendocrine systems. Physiol Rev 1989, 69: 1-32.
8. Besedovsky HO, Del Rey A: Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996, 17: 64-102.
9. Belmonte C, Cervero F: Neurobiology of nociceptors. Oxford University Press, New York. 1996.
10. Pennisi E: Tracing molecules that make the brain-body connection. Science 1997, 275: 930-931.
11. Scholzen T, Armstrong CA, Bunnet NW, et al.: Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune system. Exp Dermatol 1998, 7: 81-96.
12. Scholzen TE, Brzoska T, Kalden DH, et al.: Effect of ultraviolet light on the release of neuropeptides and neuroendocrine hormone in the skin: mediators of photodermatitis and cutaneous inflammation. J Invest Dermatol Symp Proc 1999, 4: 55-9.
13. Kjartansson J, Dalsgaard CJ, Jonsson CE: Decreased survival of experimental critical flaps in rats after sensory denervation with capsaicin. Plast Reconstr Surg 1987, 79: 218-21.
14. Maggi CA: The effects of tachykinins on inflammatory and immune cells. Regul Peptides 1997, 70: 75-90.
15. Reubi JC, Horisbergar U, Kappeler A, et al.: Localization of receptors for vasoactive intestinal peptide, somatostatin and substance P in distinct compartments of human lymphoid organs. Blood 1998, 92: 191-7.
16. Gibbins IL, Wattchow D, Coventry B: Two immunohistochemically identified populations of calcitonin gene-related peptide (CGRP)-immunoreactive axons in human skin. Brain Res 1987, 414 (1): 143-8.
17. Wallengren J, Ekman R, Sundler F: Occurrence and distribution of neuropeptides in the human skin. An immunocytochemical and immunochemical study on normal skin and blister fluid from inflammed skin. Acta Derm Venerol (Stockh) 1987, 67: 185-92.
18. Johansson O: A detailed account of NPY-immunoreactive nerves and cells of the human skin. Comparison with VIP-, substance P- and PHI-containing structures. Acta Physiol Scand 1986, 128: 147-53.
19. Lundberg JM, Hokfelt T, Anggard A, et al.: Neuropeptides with vascular activity: VIP, PHI, NPY and substance P. Bibl Cardiol 1984, 38: 60-9.
20. Eedy DJ, Shaw C, Armstrong EP, et al.: Vasoacive intestinal peptide (VIP) and peptide histidine methionine (PHM) in human eccrine sweat glands: demonstration of innervation, specific binding sites and presence in secretions. Br J Dermatol 1990, 123: 65-76.
21. Bianchi B, Matucci Danesi A, Rossi R, et al.: Characterization of [3H] substance P binding sites in human skin. J Eur Acad Dermatol Venerol 1999, 12: 6-10.
22. Misery L: Langerhans cells in the neuro-immuno-cutaneous system. J Neuroimmunol 1998, 89: 83-7.
23. Misery L: Skin, immunity and the nervous system. Br J Dermatol 1997, 137: 843-50.
24. Eedy DJ: Neuropeptides in skin. Br J Dermatol 1993, 128: 597-605.
25. O'Sullivan RL, Lipper G, Lerner EA: The neuro-immuno-cutaneous-endocrine network: relationship of mind and skin. Arch Dermatol 1998, 134: 1431-1435.
26. Theoharides TC: The mast cell: a neuroendocrine master player. Int J Tissue React 1996, 18: 1-21.
27. Takahashi KT, Nakanishi S, Imamura S: Direct effects of cutaneous neuropeptides on adenyl cyclase activity and proliferation in a keratinocyte cell line: stimulation of cyclic AMP formation by CGRP and VIP/PHM, and inhibition by NPY through G protein-coupled receptors. J Invest Dermatol 1993, 101: 646-51.
28. Lundeberg L, Nordlind K: Vasoactive intestinal polypeptide in allergic contact dermatitis: an immunohistochemical and radioimmunoassay study. Arch Dermatol Res 1999, 291: 201-6.
29. Kakurai M, Fujita N, Murata S, et al.: Vasoactive intestinal peptide regulates its receptor expression and functions of human keratinocytes via type I vasoacive intestinal peptide receptors. J Invest Dermatol 2001, 116: 743-9.
30. Nissen JB, Lund M, Stengaard-Pedersens K, et al.: Enkephalin-like immunoreactivity in human skin is found selectively in fractions of CD68 positive dermal cells: increase of enkephalin positive cells in lesional psoriasis. Arch Dermatol Res 1997, 289: 265-71.
31. Nissen JB, Avrach WW, Hansen ES, et al.: Decrease in enkephalin levels in psoriatic lesions after calcipotriol and mometasone fluroate treatment. Dermatology 1999, 198: 11-7.
32. Johansson O, Liu PY, Lindberger M, et al.: An immunohistochemical study of neuroactive substance in the skin of atopic dermatitis. Eur J Dermatol 1995, 5: 516-23.
33. Fantini F, Johansson O: Neurochemical markers in human cutaneous Merkel cells. An immunocytochemical investigation. Exp Dermatol 1995, 4: 365-71.
34. Pincelli C, Hakke AR, Bernasii L, et al.: Autocrine nerve growth factor protects human keratinocytes from apoptosis through its high affinity receptor (trk): a role bd-2. J Invest Dermatol 1997, 109: 757-64.
35. DiMarco E, Marchisto PC, Bondaza S, et al.: Growth-regulated synthesis and secretion of biologically active nerve growth factor by human keratinocytes. J Biol Chem 1991: 266: 21718-22.
36. Hattori A, Iwaski S, Murase K, et al.: Tomor necrosis factor is markedly synergistic with interleukin 1 and interferon gamma in stimulating the production of nerve growth factor in fibroblasts. FEBS lett., 1994, 340: 177-80.
37. Vos P, Stark F, Pittman RN: Merkel cells in vitro production of nerve growth factor and selective interaction with sensory neurons. Dev Biol 1991, 144: 281-300.
38. Yaar M, Eller MS, DiBenedetto P, et al.: The trk family of receptors mediates nerve growth factor and neurotrophin-3 effects in melanocytes. J Clin Invest 1994, 94: 1550-62.
39. Burbach GJ, Kim KH, Zivony AS, et al.: The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor. J Invest Dermatol 2001, 117 (5): 1075-82.
40. Grewe M, Vogelsang K, Ruzicka T, et al.: Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. J Invest Dermatol 2000, 114 (6): 1108-12.
41. Calvo C, Chavanel G, Senik A: Substance P enhances II-2 expression in activated human T cells. J Immunol 1992, 148: 3498-504.
42. Kincy-Cain T, Bost KL: Substance P-induced IL-12 production by murine macrophages. J Immunol 1997, 158: 2334-9.
43. Lai J, Douglas SD, Ho W: Human lymphocytes express substance P and its receptor. J Neuroimmunol 1998, 86: 80-6.
44. Grohman U, Belladonna ML, Bianchi R, et al.: IL-12 acts directly on DC to promote nuclear localization of NF-κB and primes DC for IL-12 production. Immunity 1998, 9: 315-23.
45. Pascual DW, Xu-Amano J, Kiyono H, et aL: Substance P acts directly upon cloned B lymphoma cells to enhance IgA and IgM production. J Immunol 1991, 146: 2130-6.
46. Ansel JC, Brown JR, Payan DG, et al.: Substance P selectively activates TNF-α gene expression in murine mast cells. J Immunol 1993, 150: 4478-85.
47. Calvo CF, Chavanel G, Senik A: Substance P enhances IL-2 expression in activated human T cells. J Immunol 1992, 148: 3498-504.
48. Ansel JC, Armstrong CA, Song I, et al.: Interactions of the skin and nervous system. J Invest Dermatol Symp Proc 1997, 2: 23-6.
49. Quinlan KL, Song IS, Bunnett NW, et al.: Neuropeptide regulation of human dermal microvascular endothelial cell ICAM-1 expression and function. Am J Physiol 1998, 275: 1580-90.
50. Quinlan KL, Song IS, Naik SM, et al.: VCAM-1 expression on human dermal microvascular endothelial cells is directly and specifically up-regulated by substance P. J Immunol, 1999, 162 (3): 1656-61.
51. Wang F, Miller I, Bottomly K, et al.: Calcitonin gene-related peptide inhibits interleukin 2 production by murine T lymphocytes. J Biol Chem 1992, 267: 21052-7.
52. Umeda Y, Takamiya M, Yoshizaki H, et al.: Inhibition of mitogen-stimulated T lymphocyte proliferation by calcitonin gene-related peptide. Biochem Biophys Res Commun 1988, 154: 227-35.
53. Torii H, Tamaki K, Granstein RD: The effect of neuropeptides/hormones on Langerhans cells. J Dermatol Sci 1998, 20 (1), 21-8.
54. Carruci JA, Ignatus R, Wel Y, et al.: Calcitonin gene-related peptide decreases expression of HLA-DR and CD86 by human dendritic cell-driven T cell-proliferative responses via the type I calcitonin gene-related peptide receptor. J Immunol 2000, 164: 3494-9.
55. Kramp J, Brown J, Cook P, et al.: Neuropeptide induction of human microvascular endothelial cell interleukin-8 (abstr.). J Invest Dermatol 1995, 104: 586.
56. Guerrero JM, Prieto JC, Elorza FL, et al.: Interaction of vasoactive intestinal peptide with human blood mononuclear cells. Mol Cell Endocrinol 1981, 21: 151-60.
57. Ganea D, Delgado M, et al.: Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP. Arch Immunol Ther Exp (Warszawa) 2001, 49 (2): 101-10.
58. Taylor AW, Streilein JW, Cousins SW: Immunoreactive VIP contributes to the immunosupressive activity of normal aqueous humor. J Immunol 1994, 153: 1080-6.
59. Delneste Y, Herbault N, Galea B, et al.: Vasoactive intestinal polypeptide synergizes with TNF-? in inducing human dendritic cell maturation. J Immunol 1999, 163: 3071-5.
60. Bondesson L, Nordlind K, Liden S, et al.: Dual Effects of vasoactive intestinal peptide (VIP) on leucocyte migration. Acta Physiol Scand 1991, 141: 477-81.
61. Pincelli C, Fantini F, Giannetti A: Neuropeptides and skin inflammation. Dermatology 1993, 187: 153-8.
62. Bascom R, Meggs WJ, Frampton M, et al.: Neurogenic inflammation, with additional discussion of cental and perceptual integration of nonneurogenic inflammation. Environ Health Perspect 1997, 105: 531-7.
63. Gamse R, Holzer P, Lembeck F, et al.: Decrease in substance P in primary afferent neurone and impairment of neurogenic plasma extravasation by capsaicin. Br J Pharmacol 1980, 68: 207-13.
64. Foster CA, Mandak B, Kromer E, et al.: The neuropeptide substance P is chemotactic for human T cells (abstr.). J Invest Dermatol 1991, 96: 537.
65. Foster CA, Mandak B, Kromer E, et al.: Calcitonin gene-related peptide is chemotactic for human T lymphocytes. Ann N Y Acad Sci 1992, 657: 397-404.
66. Foreman J, Jordan C: Histamine release and vascular changes induced by neuropeptides. Agents Actions 1983, 13: 105-16.
67. Brain SD, Tippins JR, Morris HR, et al.: Potent vasodilatator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol 1986, 87: 533-6.
68. Brain SD, Newbold P, Kajekar R: modulation of the release and activity of neuropeptides in the microcirculation. Can J Physiol Pharmacol 1995, 73: 995-8.
69. Fuller RW, Conradson TB, Dixon CM, et al. Sensory neuropeptide effects in human skin. Br J Pharmacol 1987, 92 (4): 781-8.
70. Michel MC, Schlicker E, Fink K, et al.: Distinction of NPY receptors in vitro and vivo. I. NPY (18-36) discriminates NPY receptor subtypes in vitro. Am J Physiol 1990, 259: E131-9.
71. Agro A, Stanisz AM: Neuroimmunomodulation: classical and non-classical cellular activation. Adv Neuroimmunol 1995, 5: 311-9.
72. Wallengren J, Hakanson R: Effects of substance P, neurokinin A and calcitonin gene-related peptide in human skin and their involvement in sensory nerve-mediated responses. Eur J Pharmacol 1987, 143: 267-73.
73. Mazurek N, Pecht I, Teichberg VI, et al.: The role of the N-terminal tetrapeptide in the histamine-releasing action of substance P. Neuropharmacol 1981, 20: 1025-7.
74. Ziche M, Morbidelli L, Pacini M, et al.: Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvascular Res 1990, 40: 264-78.
75. Haegerstrand A, Dalsgaard CJ, Jozon B, et al.: Calcitonin gene-related peptide stimulates proliferation if human endothelial cells. Proc Natl Acad Sci USA 1990, 87: 3299-303.
76. Bull HA, Brickell PM, Dowd PM, et al.: The pro-proliferative effects of vasoactive peptides and protein tyrosine phosphorylation in human dermal microvascular endothelial cells (abstr.). J Invest Dermatol 1992, 98: 616.
77. Gazelius B, Brodin E, Olgart L, et al.: Evidence that substance P is a mediator of antidromic vasodilatation using somatostatin as an inhibitor. Acta Physiol Scand 1981, 113: 155-9.
78. Gianneti A, Girolomoni G: Skin reactivity to neuropeptides in atopic dermatitis. Br J Dermatol 1989, 121 (6): 681-8.